Phospholipase C-related catalytically inactive protein (PRIP) controls KIF5B-mediated mediated insulin secretion

RESEARCH ARTICLE

Satoshi Asano1, Tomomi Nemoto2, Tomoya Kitayama1, Kae Harada1, Jun Zhang1, Kana Harada1, Isei Tanida3, Masato Hirata4 and Takashi Kanematsu1,*

ABSTRACT

We previously reported that phospholipase C-related catalytically inactive protein (PRIP)-knockout mice exhibited hyperinsulinaemia. Here, we investigated the role of PRIP in insulin granule exocytosis using Prp-knockdown mouse insulinoma (MIN6) cells. Insulin release from Prp-knockdown MIN6 cells was higher than that from control cells, and Prp knockdown facilitated movement of GFP-phogrin-labeled insulin secretory vesicles. Double-immunofluorescent staining and density step-gradient analyses showed that the KIF5B motor protein co-localized with insulin vesicles in Prp-knockdown MIN6 cells. Knockdown of GABA-A-receptor-associated protein (GABARAP), a microtubule-associated PRIP-binding partner, by Gabarap silencing in MIN6 cells reduced the co-localization of insulin vesicles with KIF5B and the movement of vesicles, resulting in decreased insulin secretion. However, the co-localization of KIF5B with microtubules was not altered in Prp- and Gabarap-knockdown cells. The presence of unbound GABARAP, freed either by an interference peptide or by Prp silencing, in MIN6 cells enhanced the co-localization of insulin vesicles with microtubules and promoted vesicle mobility. Taken together, these data demonstrate that PRIP and GABARAP function in a complex to regulate KIF5B-mediated insulin secretion, providing new insights into insulin exocytic mechanisms.

KEY WORDS: GABARAP, Insulin secretion, KIF5B, PRIP, Vesicle transport

INTRODUCTION

Insulin secretion from pancreatic β-cells is a highly dynamic process regulated by multiple stimuli, including nutrients, hormones, and neuronal inputs. Stimulation by glucose induces a biphasic pattern of insulin release. First-phase insulin release occurs within a few minutes after exposure to elevated glucose, and it is followed by a more sustained second phase (Rorsman et al., 2000). The first phase, during which insulin granules that are pre-docked on the plasma membrane and/or recruited from a readily releasable pool become fused, has been extensively investigated. However, the precise mechanisms underlying the second phase are poorly understood. Second phase release correlates with mobilization of insulin-containing granules from the releasable pool into the cell periphery, which is mediated by microtubules. Insulin-containing cargo transport is regulated by the motor protein kinesin-1/KIF5 (Balccon et al., 1992; Cui et al., 2011; Meng et al., 1997; Varadi et al., 2002; Varadi et al., 2003).

Phospholipase C (PLC)–related but catalytically inactive protein (PRIP) was first identified as a novel inositol 1,4,5-trisphosphate-binding protein that has high homology to PLC-δ1, but lacks PLC activity (Kanematsu et al., 1996; Kanematsu et al., 1992; Kanematsu et al., 2000; Takeuchi et al., 1997; Takeuchi et al., 1996; Yoshida et al., 1994). We previously reported the effect of PRIP on inositol 1,4,5-trisphosphate-mediated Ca2+ release from the endoplasmic reticulum (Harada et al., 2005; Takeuchi et al., 2000). There are 2 isoforms of mammalian PRIP, PRIP1, which is present mainly in the brain, and PRIP2, which is ubiquitously expressed (Kanematsu et al., 1992; Kikuno et al., 1999; Uji et al., 2002). To elucidate the physiological function of PRIP, we identified a variety of PRIP-binding partners, including protein phosphatase 1β (Yoshimura et al., 2001), protein phosphatase 2A (Kanematsu et al., 2006; Sugiyama et al., 2012), GABA-A receptor-associated protein (GABARAP) (Kanematsu et al., 2002), the β subunits of GABA-A receptors (Terunuma et al., 2004), and the activated form of Akt (Fujii et al., 2010). These findings led us to investigate the possible involvement of PRIP in GABA-A receptor functions. PRIP regulates GABA-A receptor cell surface translocation and endocytosis through phosphorylation of the receptor by these aforementioned PRIP-binding partners (Fujii et al., 2010; Kanematsu et al., 2007; Kanematsu et al., 2006; Mizokami et al., 2007; Terunuma et al., 2004). We also previously reported increased levels of plasma insulin in Prp1-knockout mice and serum gonadotropins in Prp1 and Prp2 double knockout (Prp-DKO) mice (Doira et al., 2001; Matsuda et al., 2009), suggesting an inhibitory role for PRIP in dense-core vesicle secretion.

GABARAP, a member of the microtubule-associated protein family, is composed of N-terminal (residues 1–22) and central (residues 40–68) regions that interact with microtubules and PRIP, respectively, and a C-terminal glycine at residue 116 that is covalently conjugated to phosphatidylethanolamine through a ubiquitination-like system (Ichimura et al., 2000; Kanematsu et al., 2005; Wang and Olsen, 2000). Northern blot analysis revealed that GABARAP expression is ubiquitous (Okazaki et al., 2000). Therefore, GABARAP can regulate a variety of cell functions, including the functions of GABA-A receptor-expressing neurons. Indeed, GABARAP has been reported to promote the
cell surface expression of angiotensin II type I receptor (Cook et al., 2008), transient receptor potential vanilloid 1 (Laínez et al., 2010), and κ-opioid receptor (Chen et al., 2011) by facilitating trafficking along the secretory vesicle pathway. GABARAP interacts with PRIP and regulates the recruitment of γ subunit-containing GABA_{A} receptors to the cell surface (Boileau et al., 2005; Chen et al., 2005; Kanematsu et al., 2002; Leil et al., 2004; Mizoizaki et al., 2007).

In this study, we knocked down Prip or Gabarap in the MIN6 mouse insulinoma cell line using specific small interfering RNAs (siRNAs), and then analyzed glucose-induced insulin secretion from these cells. In addition, we investigated the importance of PRIP and GABARAP interaction in insulin vesicle movement. Finally, by analyzing pancreatic islets from wild-type and Prip-knockout mice, we proposed that PRIP regulates second phase insulin secretion.

**MATERIALS AND METHODS**

**Antibodies and reagents**

An anti-GABARAP antibody (PM037) that recognizes the N-terminal region (amino acids 1–39) was from Medical and Biological Laboratories (Nagoya, Japan). Anti-insulin/proinsulin antibody (2IP10) was from HyTest (Turku, Finland). Anti-KIF5 antibody (SAB3500282), Anti-KIF5 antibody (D66), and anti-SNAP25 antibody (S5187) were from Sigma–Aldrich (St Louis, MO, USA). Anti-Ptprn2 (phogrin) antibody (PAB15812) was from Abnova (Taipei, Taiwan). Anti-Rab27a antibody (17817-1-AP) was from Proteintech (Chicago, IL, USA). Anti-HaloTag antibody was from Promega (Madison, WI, USA). Anti-tubulin beta antibody (RB-9249) was from Thermo Fisher Scientific (Waltham, MA, USA). Anti-syntxin1 antibody (sc-12736) was from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-PRIP1 and anti-PRIP2 polyclonal antibodies were described previously (Kanematsu et al., 2002; Otsubi et al., 1999). FITC-conjugated anti-myc antibody (R953-25), Alexa Fluor 488 anti-rabbit IgG (A11008), and Alexa Fluor 555 and 405 anti-mouse IgG (A21422 and A31553, respectively) antibodies were from Invitrogen (Carlsbad, CA, USA). Peroxidase-conjugated anti-rabbit (P0399) and anti-mouse (NA9310) IgG antibodies were from Dako (HyTest, Turku, Finland). Anti-insulin/proinsulin antibody (2IP10) was from HyTest (Turku, Finland). Anti-KIF5 antibody (SAB3500282), Anti-KIF5 antibody (D66), and anti-SNAP25 antibody (S5187) were from Sigma–Aldrich (St Louis, MO, USA). Anti-Ptprn2 (phogrin) antibody (PAB15812) was from Abnova (Taipei, Taiwan). Anti-Rab27a antibody (17817-1-AP) was from Proteintech (Chicago, IL, USA). Anti-HaloTag antibody was from Promega (Madison, WI, USA). Anti-tubulin beta antibody (RB-9249) was from Thermo Fisher Scientific (Waltham, MA, USA). Anti-syntxin1 antibody (sc-12736) was from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-PRIP1 and anti-PRIP2 polyclonal antibodies were described previously (Kanematsu et al., 2002; Otsubi et al., 1999). FITC-conjugated anti-myc antibody (R953-25), Alexa Fluor 488 anti-rabbit IgG (A11008), and Alexa Fluor 555 and 405 anti-mouse IgG (A21422 and A31553, respectively) antibodies were from Invitrogen (Carlsbad, CA, USA). Peroxidase-conjugated anti-rabbit (P0399) and anti-mouse (NA9310) IgG antibodies were from Dako (Glostrup, Denmark) and GE Healthcare (Pittsburgh, PA, USA), respectively. TurboGFP-C-terminally tagged mouse Ptprn2/phogrin construct (NM_012115) was from OriGene (Rockville, MD, USA). Gabarap-sirNA (1, 2) (s80666, s80665) and Kif5b-sirNA (1, 2) (s68783, s68781) were from Life Technologies (Carlsbad, CA, USA). Mouse Prip1-sirNAS (1, 2, 3) and Prip2-sirNAS (1, 2, 3) were described previously (Kiyatama et al., 2013).

**Plasmid construction**

YFP-tagged human GABARAP (Tanida et al., 2006) was kindly provided by Dr E. Kominami (Juntendo University, Japan). GABARAP4-67 was cloned into the pIRE2-DsRed-Express vector (Takara, Shiga, Japan) and a HaloTag-containing pcDNA3.1 vector (produced in our laboratory). GABARAP2-35 was cloned as a fusion with a myc epitope. DsRed-PRIP1 has been described previously (Kanematsu et al., 2006; Kominami et al., 2007). GABARAP2-35 was cloned as a fusion with a myc epitope. DsRed-PRIP1 has been described previously (Kanematsu et al., 2006; Kominami et al., 2007). GABARAP2-35 was cloned as a fusion with a myc epitope. DsRed-PRIP1 has been described previously (Kanematsu et al., 2006; Kominami et al., 2007). GABARAP2-35 was cloned as a fusion with a myc epitope. DsRed-PRIP1 has been described previously (Kanematsu et al., 2006; Kominami et al., 2007). GABARAP2-35 was cloned as a fusion with a myc epitope. DsRed-PRIP1 has been described previously (Kanematsu et al., 2006; Kominami et al., 2007).
Immunoprecipitation assay

The association of GABARAP with PRIP was analyzed using MIN6 cells expressing myc-tagged GABARAP with or without high glucose stimulation. Cells were homogenized in a buffer containing 20 mM HEPES-Na (pH 7.5), 150 mM NaCl, 0.1% Triton X-100, 10% (w/v) glycerol, and a mixture of protease inhibitors, and then centrifuged at 13,000 × g for 60 min at 4°C. The resulting supernatant was incubated with 5 μg of anti-myc antibody or control rabbit IgG, and then incubated with protein G-Sepharose overnight at 4°C with gentle rotation. After gentle centrifugation, the precipitates were boiled in SDS sample buffer, separated by SDS-PAGE, and analyzed by western blotting using anti-PRIP1 and anti-PRIP2 antibodies. To visualize the antibody–protein complexes, SuperSignal West Femto extended duration substrate (Thermo Fisher Scientific) was used. Imaging of western blots was performed using an ImageQuant LAS 4000 mini (GE Healthcare).

Isolation of mouse pancreatic islets

Experimental procedures involving animals and animal handling were performed according to the guidelines of Hiroshima University and were approved by the Animal Care and Use Committee of Hiroshima University. Eight- to twelve-week-old Prip-DKO mice ( Mizokami et al., 2007) were killed by cervical dislocation, and pancreatic islets were isolated by collagenase digestion (Takahashi et al., 1997). Islets were maintained for 12 h in DMEM containing 10% FBS at 37°C and 5% CO₂.

Two-photon excitation imaging

Exocytosis was visualized by using a fluid-phase tracer, sulforhodamine B (0.7 mM; Molecular Probes, Carlsbad, CA, USA) in an assay solution (140 mM NaCl, 5 mM KCl, 2 mM CaCl₂, 1 mM MgCl₂, and 10 mM HEPES-NaOH) containing 2.8 mM (low) or 20 mM (high) glucose with two-photon excitation imaging. The islets were imaged with an inverted microscope (IX70; Olympus, Tokyo, Japan) and a laser-scanning microscope (FluoView; Olympus) equipped with a water-immersion objective lens (UplanApo60xW/IR; NA, 1.2), as previously described (Kasai et al., 2005). Two-photon excitation was performed at 830 nm, and the fluorescence signals of the Ca²⁺ indicator fura-2 (Kd: ~200 nM) and the polar tracer sulforhodamine B were separated by a dichroic filter and captured at 420–560 and 570–650 nm, respectively, and images were acquired every 1 sec. In an individual, 4,500–5,500 μm² region of interest in islets containing approximately 40–60 cells, we analyzed abruptly appearing small fluorescent spots on the plasma membrane, which were recorded as “exocytic events”.

Statistical analysis

Data are presented as mean ± s.e. or s.d. Original data were compared by Dunn’s multiple comparison test, unless otherwise stated.

RESULTS

PRIP gene silencing in MIN6 cells increases insulin secretion and the mobility of insulin vesicles

Prip1-knockout mice exhibit a hyperinsulinemic phenotype (Doira et al., 2001). To verify the involvement of PRIP in the regulation of insulin granule exocytosis, we performed an insulin secretion assay using MIN6 cells transfected with both Prip1-siRNAs (1, 2, 3) and Prip2-siRNAs (1, 2, 3) as well as a scrambled control siRNA. The expression of PRIP1 and PRIP2 was assessed by western blotting, which showed that their expression was markedly reduced within 2 days after transfection (Fig. 1A). To assess this effect, a different pair of Prip1- and Prip2-siRNAs was transfected into MIN6 cells, and these siRNAs also reduced PRIP1 and PRIP2 expression (supplementary material Fig. S1A). The release of insulin was then measured before and after stimulation with high glucose (30 mM). Samples were successively collected at 0–4 min, 4–7 min, and 7–10 min after stimulation. In control cells, insulin release was 6.8-fold and 4.3-fold higher than the basal level (before stimulation, −2–0 min) at 4–7 and 7–10 min, respectively (Fig. 1B). Similar 7.0-fold and 5.4-fold increases were also observed in Prip-knockdown cells during the same time intervals. The upregulation of insulin was significant in the Prip-knockdown cells at 7–10 min, suggesting that PRIP negatively regulates insulin release in MIN6 cells, particularly at the late phase. A similar result was observed when another pair of Prip siRNAs [Prip1-siRNA (3) and Prip2-siRNA (3)] was used ( supplementary material Fig. S1D).

Insulin vesicles are transported from the releasable pool to the cell surface, and then secreted (Rorsman et al., 2000). PRIP regulates neuronal surface expression of γ subunit-containing GABA<sub>A</sub> receptors by controlling GABARAP function ( Mizokami et al., 2007). These findings suggest that PRIP and/or GABARAP may participate in the transport of insulin vesicles. To determine if PRIP participates in insulin vesicle movement, we performed time lapse imaging using GFP-tagged phogrin, which has been reported to localize to the membrane of insulin secretory granules (Wasmeier and Hutton, 1996), allowing for monitoring of anterograde insulin-containing vesicle translocation to the cell surface (Varadi et al., 2002). First, we evaluated the localization of phogrin and insulin vesicles in MIN6 cells by immunocytochemistry (supplementary material Fig. S2). Both signals were highly co-localized, indicating that insulin vesicle movement can be monitored by following GFP-tagged phogrin movement.

Transfection of Prip-siRNAs into MIN6 cells appeared to trigger the vigorous movement of insulin vesicles, even in low glucose conditions, which was qualitatively analyzed by measuring the rate of moving vesicles, and vigorous movement was defined as vesicles moving with a velocity exceeding 10 μm per min ( Nakajima et al., 2012). The mean mobility index was also increased in Prip-knockdown cells (Fig. 1C–E). When the cells were stimulated with high glucose, the percentage of vigorously moving vesicles during the period from 600 sec to 690 sec after stimulation was increased in Prip-knockdown cells (Fig. 1C,D), and the accumulated distance was approximately 2-fold higher (Fig. 1E). These results suggest that PRIP deficiency promotes phogrin-positive vesicle movement.

KIF5B-regulated insulin vesicle transport in MIN6 cells is enhanced by Prip silencing

Insulin vesicle movement is regulated by kinesin-1 (conventional kinesin). KIF5, the heavy chain of kinesin-1, has three subtypes, KIF5A, KIF5B, and KIF5C; KIF5B is only detected in isolated mouse pancreatic islets and participates in insulin secretion ( Cui et al., 2011). By using reverse transcription-polymerase chain reaction, we confirmed that MIN6 cells expressed Kif5b, but not Kif5a or Kif5c (supplementary material Fig. S3A). To examine the involvement of KIF5B in insulin secretion, we analyzed insulin secretion and insulin vesicle mobility in MIN6 cells transfected with two different Kif5b-siRNAs (1 and 2). KIF5B expression, as assessed by western blotting, was markedly reduced but not completely abolished (supplementary material Fig. S1B). KIF5B signals were rarely observed in Kif5b-siRNA (1)-transfected cells by immunocytochemical analysis (supplementary material Fig. S3B). Insulin secretion was assayed by measuring insulin levels in culture medium collected at 0–4 min, 4–7 min, and 7–10 min after high glucose stimulation (Fig. 2A). The upregulation of insulin secretion at 7–10 min following high glucose stimulation was significantly decreased in Kif5b-siRNA (1) knockdown cells, whereas insulin secretion was rebounded when Prip1, Prip2, and Kif5b were simultaneously knocked down (Fig. 2A).
Similar patterns were also observed in an insulin vesicle mobility assay (Fig. 2B). Presumably, the rebound observed following simultaneous Prip and Kif5b knockdown was the result of the enhanced function of the remaining endogenous KIF5B, suggesting an inhibitory role for PRIP in kinesin-mediated insulin secretion. A similar result was obtained in cells transfected with a different Kif5b-siRNA (2) in an insulin secretion assay (supplementary material Fig. S1D).

We then examined the relationship between PRIP and KIF5B in insulin vesicle transport under high glucose conditions. Co-localization analysis of KIF5, β-tubulin (microtubules), and insulin vesicles was performed by double-staining immunocytochemistry in Prip-siRNA-transfected MIN6 cells. The localization of KIF5 and β-tubulin in scrambled siRNA-transfected and Prip-knockdown cells were not different (representative images and the overall data are shown in Fig. 2C and Fig. 2F, respectively). However, the co-localization of KIF5 with insulin vesicles and of insulin vesicles with β-tubulin was significantly enhanced (for KIF5 and β-tubulin, see Fig. 2D,G and Fig. 2E,H, respectively). These data suggest that PRIP deficiency promotes the interaction of insulin vesicles with KIF5 without affecting the co-localization between KIF5 and microtubules.

To further analyze the distribution of insulin vesicles with KIF5 in MIN6 cells, we carried out an OptiPrep™ discontinuous gradient fractionation assay. The secretory granule proteins phogrin and Rab27a (Arden et al., 2004; Yi et al., 2002) were located in fraction 11, which was at the interface between 7.5% and 18% OptiPrep™ where insulin was also accumulated (Fig. 3A,B). Therefore, fraction 11 was designated the insulin dense-core granular fraction. In response to high glucose stimulation, KIF5 was detected in fraction 11 (compare Fig. 3A to Fig. 3B). Prip deficiency appeared to induce KIF5 localization with the secretory vesicle fraction under low glucose conditions, and this was unchanged when cells were stimulated with high glucose (compare Fig. 3A to Fig. 3C and Fig. 3D). The increased KIF5 in the secretory vesicle fraction was then quantified by western blotting (Fig. 3E,F). Prip deficiency caused a 2.4-fold increase in the amount of KIF5 present in the vesicle fraction compared to the amount in the control MIN6 cells under low glucose conditions, and the increase was unchanged under high glucose conditions (Fig. 3F), indicating that Prip deficiency promotes the co-localization of insulin vesicles with KIF5B, independent of extracellular glucose concentration.

**GABARAP and PRIP are required for insulin secretion**

PRIP binds directly to GABARAP, and this complex facilitates the recruitment of GABARAs receptors to the cell membrane (Mizokami et al., 2007). GABARAP is a tubulin-binding protein.
that regulates the trafficking of GABA<sub>A</sub> receptor and other receptors (Chen et al., 2011; Cook et al., 2008; Lainez et al., 2010; Leil et al., 2004). Therefore, we next investigated the involvement of Gabarap in insulin secretion by silencing Gabarap expression using Gabarap-siRNA (1) and Gabarap-siRNA (2). Successful Gabarap knockdown was confirmed by western blotting (supplementary material Fig. S1C) and immunocytochemistry (supplementary material Fig. S4). As shown in Fig. 4A, in response to high glucose stimulation, higher levels of insulin release were observed in cells at 4–7 min and 7–10 min than at basal level (~2–0 min). Compared to the control cells, insulin secretion from the cells transfected with Gabarap-siRNA (1), was significantly decreased at both 4–7 min and 7–10 min (36% and 30% reduction, respectively), and a similar result was obtained in MIN6 cells transfected with Gabarap-siRNA (2) (supplementary material Fig. S1D). Prip knockdown reversed the decreased insulin secretion from Gabarap-siRNA (1)-transfected cells to the level observed in the control cells only during the 7–10 min time point (Fig. 4A). Furthermore, the accumulated distance traveled by the secretory vesicles was also reduced by Gabarap knockdown under high glucose conditions, which was partially potentiated by additional Prip knockdown (Fig. 4B, left panel). These results could be interpreted as follows: following additional PRIP-knockdown, the endogenous GABARAP remaining in cells after Gabarap silencing became free and promoted insulin secretion and vesicle transport, leading to an increase in insulin release and vesicle accumulation.

**Fig. 2.** KIF5B-mediated insulin vesicle transport is regulated by PRIP. (A) Insulin secretion analysis of kif5b-knockdown MIN6 cells. MIN6 cells transfected with KIF5B-siRNA (1) and Prip-siRNA mix (+) or scrambled siRNA (−) were stimulated with 30 mM glucose. Released insulin was collected and measured every 1 min. The mean percentage of total insulin content is shown. Values are presented as mean ± s.d. (n=3). (B) The average accumulated distance per vesicle was calculated. Each value is the average distance travelled by the cells relative to that of cells transfected with scrambled siRNA under high glucose (30 mM) conditions. Values are presented as mean ± s.e. (from the left in each experiment; n=120, 116, and 56, respectively). (C–E) Co-localization analyses of KIF5 (green) and β-tubulin (red) (C), KIF5 (green) and insulin (red) (D), and β-tubulin (green) and insulin (red) (E) in MIN6 cells transfected with scrambled siRNA (upper panels) or PRIP1-siRNAs (1, 2, 3) and PRIP2-siRNAs (1, 2, 3) (Prip-siRNA mix; lower panels). Cells were stimulated with 30 mM glucose for 10 min, fixed with 3.7% paraformaldehyde, subjected to immunocytochemistry with a specific antibody, and processed for confocal microscopy. The yellow and blue pseudo-colors in the PDM images show areas of high and low co-localization, respectively. Magnified images of panels C–E are shown in supplementary material Fig. S8A–C. The dotted line shows a cell edge. A set of typical images from 3 independent experiments is shown. (F–H) Statistical analysis of the co-localization experiments in panels C–E. Overlap coefficients were calculated in each experiment. Values are presented as mean ± s.d. (from the left in each graph, n=60 and 45 (F); 96 and 104 (G); 84 and 60 (H), respectively). *p<0.05, **p<0.01, ***p<0.001; n.s., not statistically significant. Scale bars: 5 μm.
mobility. In turn, Prip overexpression in MIN6 cells decreased the mobility of insulin vesicles, and this effect was further inhibited by transfection with Gabarap-siRNA (Fig. 4B, right panel). These data suggest that a complex of PRIP and GABARAP regulates KIF5B-mediated insulin vesicle transport; GABARAP appears to promote vesicle trafficking, whereas PRIP blocks this effect.

To investigate the effect of Gabarap silencing, we examined the co-localization of insulin vesicles with KIF5 and microtubules under high glucose conditions. Gabarap knockdown had little effect on the localization of KIF5 with β-tubulin (Fig. 4C,F). However, insulin vesicles co-localized with KIF5 or β-tubulin to a lesser extent following Gabarap knockdown (for KIF5 and β-tubulin, see Fig. 4D,G and Fig. 4E,H, respectively). Consistently, silencing of Kif5b had little effect on the localization of GABARAP and insulin vesicles (supplementary material Fig. S3C). These data suggest that GABARAP facilitates localization of insulin vesicles on microtubules, probably through its binding to insulin vesicles and microtubules; thus, GABARAP presents insulin vesicles to KIF5. Since GABARAP associates with the microtubules through its microtubule-binding domain (amino acid residues 1–22) (Wang and Olsen, 2000), we next examined co-localization using a plasmid expressing a GABARAP protein (GABARAP2–35) that inhibits the binding of GABARAP with tubulin. As shown in Fig. 4I,J, the co-localization of insulin vesicles with KIF5 was significantly inhibited in cells expressing GABARAP2–35 peptide, suggesting the importance of the interaction between GABARAP and microtubules for the co-localization of insulin vesicles with KIF5.

We next examined the effect of Prip silencing on GABARAP functions. In Prip-knockdown MIN6 cells under high glucose conditions, GABARAP was highly co-localized with insulin vesicles and β-tubulin (see PDM panels in Fig. 5A and Fig. 5B, respectively) compared to the control cells. Consistently, fractionation analysis using an OptiPrep™ discontinuous gradient revealed that the GABARAP signal in the secretory vesicle fractions was faint in control cells under low glucose conditions, but was higher in Prip-knockdown cells under both low and high glucose conditions (supplementary material Fig. S5A,B). These results suggest that PRIP negatively regulates the association of GABARAP with insulin vesicles and microtubules in MIN6 cells.

A GABARAP peptide that interferes with its binding to PRIP mediates insulin vesicle localization with microtubules and KIF5, which facilitates insulin vesicle transport

The PRIP–GABARAP complex may regulate KIF5B-mediated insulin vesicle transport. PRIP binds to GABARAP at amino acid residues 40–68, and a peptide that includes these residues inhibits binding (Kanematsu et al., 2002; Kanematsu et al., 2005; Kanematsu et al., 2006; Mizokami et al., 2007). Therefore, we used this peptide to examine the importance of this association for insulin secretion. PRIP1 co-precipitated with HaloTag®-fused GABARAP40–67, but not with control IgG (supplementary material Fig. S5C), indicating that the GABARAP40–67 peptide...
Fig. 4. GABARAP enhances insulin vesicle transport by regulating insulin vesicle localization with KIF5 and β-tubulin, which is negatively regulated by PRIP. (A) Insulin secretion from Gabarap-knockdown MIN6 cells. Gabarap-siRNA-transfected MIN6 cells co-transfected with or without Prip1-siRNAs (1, 2, 3) and Prip2-siRNAs (1, 2, 3) (Prip siRNA mix) were cultured for 2 days. The cells were stimulated with 30 mM glucose, and the released insulin was measured every 1 min. The mean value for the percentage of total insulin content is shown. Values are presented as mean ± s.d. (n=3). (B) The mean accumulated distance per vesicle was calculated under high-glucose conditions. Each value is presented relative to the distance traveled by the control (black bar). Values are presented as mean ± s.e. (from the left, n=47, 168, 112, 45, 169, and 66). (C–J) Co-localization analyses of KIF5 (green) and β-tubulin (red) (C), KIF5 (green) and insulin (red) (D), and β-tubulin (green) and insulin (red) (E) in MIN6 cells transfected with scrambled siRNA (upper panels) or Gabarap-siRNA (1) (lower panels), or KIF5 and insulin (I) in MIN6 cells transfected with an empty vector (upper panels) or myc-tagged GABARAP2–35 (lower panels) after 30 mM glucose stimulation for 10 min. Cells were fixed with 3.7% paraformaldehyde, subjected to immunocytochemistry with each specific antibody, and processed for confocal microscopy. The yellow and blue pseudo-colors in the PDM images show areas of high and low co-localization, respectively. Magnified images of panels C–E are shown in supplementary material Fig. S8A–C. The myc-expressing cells (the left panel of each experiment) isolated with a FITC-conjugated anti-myc antibody were analyzed (I), and the arrowheads and arrows in the magnified images represent the areas of co-localization and non-colocalization between KIF5 (obtained blue images were replaced with green) and insulin (red), respectively. The single-color images are shown in supplementary material Fig. S9A. The dotted line shows a cell edge. A set of typical images from more than 81 cells in 3 independent experiments is shown. The overlap coefficient was calculated and is shown in panels F–H and J, and the values are presented as mean ± s.d. (from the left in each graph, n=96 and 100; 128 and 124; 124 and 100; 93 and 81, respectively). *p<0.05, ***p<0.001, †p<0.05, ††p<0.001; n.s., not statistically significant. Scale bars: 5 μm.
associates with PRIP. Introduction of a pIRES2-DsRed vector containing GABARAP40–67 into cells triggered dissociation of PRIP from GABARAP and increased insulin vesicle mobility in response to high glucose stimulation (Fig. 6A).

To determine if dissociation of GABARAP from PRIP regulates the co-localization of insulin vesicles with microtubules, we transfected pIRES2-DsRed/GABARAP40–67 into MIN6 cells and performed immunocytochemical analyses after high glucose stimulation. Compared to cells transfected with the empty vector, GABARAP was highly co-localized with insulin vesicles and β-tubulin (see the PDM panels and graph in Fig. 6B,C). Consequently, co-localization of insulin vesicles with β-tubulin was promoted in GABARAP40–67-expressing MIN6 cells (see PDM panel and graph in Fig. 6D), suggesting that GABARAP freed from PRIP facilitates bridging between insulin vesicles and microtubules. Although transfection of GABARAP40–67 had no effect on the localization of KIF5 with β-tubulin (see PDM panel and graph in Fig. 6E), it significantly increased the co-localization of KIF5 and insulin vesicles (see PDM panel and graph in Fig. 6F).

To further confirm the effect of GABARAP–PRIP dissociation, we examined the levels of KIF5 and GABARAP in the vesicle fraction (fraction 11 in Fig. 3A) using OptiPrep™ step-gradient analysis. Transfection of GABARAP40–67 into MIN6 cells promoted the accumulation of KIF5 (supplementary material Fig. S5D,E) and GABARAP (supplementary material Fig. S5D,F) in the vesicle fractions.

To elucidate whether PRIP and GABARAP interaction is regulated by extracellular glucose concentration, we performed an OptiPrep™ discontinuous gradient fractionation assay (supplementary material Fig. S5G) following incubation of cells in high and low glucose. More GABARAP was accumulated in the insulin vesicle fraction in high glucose than in low glucose. Furthermore, to determine if the amount of PRIP bound to GABARAP is altered in response to high glucose stimulation, we performed an immunoprecipitation assay using MIN6 cells transfected with a myc-tagged GABARAP plasmid (Fig. 7). Under low glucose conditions, PRIP1 and PRIP2 were immunoprecipitated by an anti-myc antibody, whereas the amounts of PRIP1 and PRIP2 precipitated were significantly decreased following high glucose stimulation, suggesting that extracellular glucose regulates the association of GABARAP with PRIP.

**PRIP deficiency increases the glucose-induced second phase of insulin secretion in pancreatic islets**

To confirm the physiological regulation of insulin exocytosis by PRIP, we performed an insulin perfusion assay using islets of Langerhans prepared from *Prip*-DKO pancreas. Both PRIP1 and PRIP2 were expressed in isolated wild-type pancreatic islets (supplementary material Fig. S6A). In response to stimulation with 20 mM glucose, insulin secretion was rapidly initiated (with a delay of 2 min), and was followed by long-lasting attenuating secretion. Biphasic insulin secretion is characterized as having a transient first phase that lasts for 2–7 min and a sustained second phase, which occurs over the next 7 min (Rorsman and Renström, 2003). Similar levels of insulin were released from islets isolated from wild-type and *Prip*-DKO mice in the first phase (2–7 min), whereas secretion in the second phase was significantly increased (approximately 1.9–2.6-fold) in *Prip*-DKO mice compared to wild-type mice (Fig. 8A). To analyze individual exocytic events, we conducted live imaging by using two-photon microscopy. Pancreatic islets from *Prip*-DKO and wild-type mice were stimulated by exposure to 20 mM glucose, and the abrupt appearance of small fluorescent spots (Ω-like structures) in the intracellular area were analyzed as previously described (Hatakeyama et al., 2006; Takahashi et al., 2002). The event number and occurrence time were counted, and the rate of insulin exocytosis was calculated. The number of exocytic events in the initial phase (0–4 min) did not differ between *Prip*-DKO and wild-type mice. However, insulin secretion events in *Prip*-DKO cells were significantly higher late in the first phase (4–6 min) and during the sustained second phase (6–8 min and 8–10 min) than in wild-type mice (Fig. 8B). We also quantified the distribution of maximum intensity (supplementary material Fig. S6B) and the lifetime of a secretory granule (expressed in terms of time before [T1] and after [T0] reaching peak intensity; supplementary material Fig. S6C,D), indicating that *Prip* deficiency may not affect the vesicle size and fusion kinetics of insulin granules. These results suggest that *Prip* knockout increases the insulin exocytic events during the second phase of release, but not the vesicle size and fusion kinetics of insulin granules in pancreatic islets.

In pancreatic β-cells, insulin secretion following granule fusion is triggered by extracellular Ca$^{2+}$ entry via a voltage-dependent Ca$^{2+}$ channel (Prentki and Matschinsky, 1987). We examined the role of PRIP in glucose-induced Ca$^{2+}$ influx by simultaneous imaging of Ca$^{2+}$ signals (supplementary material Fig. S7A). However, there were no significant differences in the mean values of Ca$^{2+}$ influx onset time (approximately 65 sec; supplementary material Fig. S7B), maximum Ca$^{2+}$ concentration (supplementary material Fig. S7C), and slope (Ca$^{2+}$ increase rate;
supplementary material Fig. S7D) between the genotypes. These data suggest that PRIP affects second-phase insulin release without influencing the process of glucose stimulation-induced Ca$^{2+}$ influx (i.e. glucose metabolism followed by voltage-gated Ca$^{2+}$ channel opening).

**DISCUSSION**

Insulin-containing vesicle transport is believed to involve long-range movement of the cargo by kinesin on microtubules (Balczon et al., 1992). In this study, we demonstrated that PRIP is a novel modulator of vesicle–kinesin complex formation. This complex consists of the motor protein KIF5B, the vesicle trafficking modulator GABARAP, β-tubulin (microtubules), and insulin-containing secretory vesicles. PRIP deficiency results in the localization of insulin granules with KIF5B and acceleration of vesicle trafficking. We also showed that GABARAP was involved in KIF5B-mediated vesicle trafficking as a molecule tethering the secretory vesicles to KIF5B and microtubules. These findings illuminate a novel mechanism in the regulation of insulin vesicle trafficking.

We demonstrated that PRIP and GABARAP act as a negative and a positive modulator, respectively, in the insulin secretory pathway by gene silencing with specific siRNAs in MIN6 cells. Since GABARAP is a PRIP binding partner and a modulator of receptor trafficking (Chen et al., 2011; Cook et al., 2008; Kanematsu et al., 2002; Lainez et al., 2010; Leil et al., 2004; Mizokami et al., 2007), understanding the molecular relationship between PRIP and GABARAP provides new insight into how insulin vesicle transport and secretion are regulated.

GABARAP has the ability to interact with microtubules in vivo (Wang et al., 1999; Wang and Olsen, 2000) and promote tubulin polymerization in vitro (Coyle et al., 2002; Wang and Olsen, 2000). There have been several reports that disruption of microtubule polymerization inhibits the sustained phase of insulin secretion (Farshori and Goode, 1994; Howell et al., 1982). Cytoskeletal motors such as kinesin, a two-headed processive motor, are capable of taking sequential steps along polymerized microtubules by direct binding. Many motors have been found to use an accessory protein to provide “secondary binding sites” that aid in motor action processivity (Kincaid and King, 2006). GABARAP is not a motor protein; however, GABARAP could function as a molecule that helps tether the
indicated time periods. Values are presented as mean ± s.e. (n=5 for each genotype). (A) Time course of glucose-stimulated insulin secretion from Prip-DKO and wild-type mouse pancreatic islets. Isolated pancreatic islets were stimulated with 20 mM glucose, and the amount of insulin released was measured. Insulin secretion was normalized to intracellular insulin content, and is presented as a percentage of the total intracellular content. Insulin secretion per min was compared during the indicated periods. The first and second phases were defined as 2–7 min, and over 7 min, respectively. Values are presented as mean ± s.e. (wild type, n=126; Prip-DKO, n=116). *p<0.05, **p<0.01.

Fig. 7. Dissociation of GABARAP from PRIP in response to glucose stimulation. MIN6 cells transfected with myc-tagged GABARAP were stimulated with low (5 mM) or high glucose (30 mM), followed by immunoprecipitation with an anti-myc antibody or control IgG. Immunoprecipitates were analyzed by SDS-PAGE and western blotting using the indicated primary antibodies. Similar results were obtained from 3 independent experiments.

kinesin–vesicle complex on the microtubules (Cook et al., 2008). We showed that, in addition to Prip-knockdown experiment, dissociation of PRIP from Gabarap by Gabarap40–67 facilitated the localization of GABARAP to the microtubules, insulin vesicles, and KIF5 (Fig. 5B, Fig. 6C,F), which enhanced insulin vesicle transport (Fig. 1E, Fig. 6A) and insulin secretion (Fig. 1B). Interestingly, glucose stimulation disrupted the binding of GABARAP with PRIP (Fig. 7). Gabarap-knockdown inhibited the co-localization of insulin vesicles with KIF5 (Fig. 4D,G) and attenuated vesicle transport and subsequent insulin secretion (Fig. 4A,B). Moreover, the dissociation of GABARAP from microtubules by an inhibitory peptide (myc-GABARAP2–35) significantly inhibited the co-localization of KIF5B and insulin vesicles (Fig. 4I,J). These data suggest that, in response to high extracellular glucose, GABARAP is freed from PRIP, is localized to microtubules, and tethers insulin vesicles to kinesin, allowing kinesin to move insulin vesicles to the cell periphery, which upregulates insulin secretion.

Glucose stimulation induces the disruption of actin filaments in primary β-cells and MIN6 cells (Nevins and Thurmond, 2003; Tomas et al., 2006). Disruption of a dense web, consisting of actin filaments, leads to dramatic increases in insulin secretion in the first phase (Howell and Tyhurst, 1979; Orci et al., 1972; Van Obberghen et al., 1973; Wang et al., 1990), suggesting that actin filaments impede the access of insulin granules to the cell periphery. Glucose stimulation has been shown to transiently disrupt the interaction of filamentous actin (F-actin) with t-SNARE proteins at the plasma membrane in primary β-cells and MIN6 cells (Thurmond et al., 2003). This disruption promotes insulin secretion, which is mediated by increased granule accumulation at the plasma membrane and increased t-SNARE accessibility (Jewell et al., 2008). In our study, GABARAP deficiency had an effect on insulin release in both the first phase (4–7 min) and the second phase (>7 min) after glucose stimulation. It was previously reported that GABARAP binds to microfilaments (actin) as well as microtubules (β-tubulin); the actin binding is not direct, and it may be mediated by yet unknown proteins (Wang and Olsen, 2000). Insulin vesicles move along microtubules to the cell surface, and are then transported to actin filaments by switching to myosin-driven transport (Varadi et al., 2003). Therefore, these data suggest that GABARAP may affect insulin release by regulating both microtubule- and actin filament-mediated secretory pathways.

Gao et al. recently reported that PRIP regulates the process of exocytosis that is modulated by the phospho-state of SNAP-25 in PC12 cells (Gao et al., 2012). Because PC12 cells do not express intrinsic PRIP1 and PRIP2, the authors exogenously transfected Prip1 and measured adrenaline secretion. PRIP overexpression inhibited adrenaline release 20–30 min after forskolin stimulation, but did not inhibit release occurring less than 10 min after stimulation. However, little is known about glucose-induced insulin secretion via PRIP-mediated SNAP-25 phosphorylation in pancreatic β-cells, and the involvement of PRIP in SNARE complex-regulated exocytosis remains to be confirmed.

Taken together, this study extends our understanding of the physiological regulation of PRIP and suggests a novel function for GABARAP in insulin exocytosis. PRIP negatively regulates the insulin secretory pathway by inhibiting the formation of a complex among GABARAP, insulin vesicles, and microtubules. Furthermore, GABARAP facilitates the anchoring of KIF5 associated with insulin granules on microtubules leading to insulin vesicle trafficking. In conclusion, the PRIP–GABARAP complex-regulated vesicle trafficking system constitutes novel secretory machinery for insulin exocytosis. This finding may
provide new therapeutic approaches for diabetes, such as \( \beta \)-cell implantation. It may be possible to produce a pancreatic \( \beta \)-cell that efficiently secretes insulin by silencing PRIP or by transfecting an interference peptide targeted at the interaction between PRIP and GABARAP.

Acknowledgements

We thank Ms Atsuko Shintani and Ms Tamaki Kise at the National Institute for Physiological Sciences and Dr Hiroki Katai at Hiroshima University for technical assistance. This work was performed at the Analysis Center of Life Science, Natural Science Center for Basic Research and Development, Hiroshima University.

Competing interests

The authors have no competing interests to declare.

Author contributions

S.A. chiefly performed the experiments and wrote a draft of the manuscript. T.N. conducted the two-photon time-lapse microscopy experiments. T. Kitahara, K.H., J.Z., and T.N. and I.T. participated in data collection and analyses. M.H. was involved in the study design. T. Kanematsu designed the project, analyzed the two-photon microscopy data, and wrote the manuscript. All the authors participated in the discussion of the results and commented on the manuscript.

Funding

This work was supported by the Funding Program for Next Generation World-Leading Researchers [LS087 to T. Kanematsu], and by grants from JSPS KAKENHI [grant numbers 24229009 to M.H., 25861756 to S.A.].

References


Fig. S1. Silencing of Prip, Kif5b, and Gabarap in MIN6 cells. (A–C) Western blot analyses. MIN6 cells were transfected with the indicated siRNA(s): a control siRNA, a pair of Prip1- and Prip2-siRNAs, or a Prip-siRNA mix (a mixture of Prip1-siRNAs (1, 2, 3) and Prip2-siRNAs (1, 2, 3)) (A), Kif5b-siRNA (1) and Kif5b-siRNA (2) (B), and Gabarap-siRNA (1) and Gabarap-siRNA (2) (C), and were cultured for 2 days. Whole cell lysates were analyzed by western blotting. Equivalent amounts of protein were loaded into each well (see β-tubulin staining). The expression level of each target protein was lower in their respective siRNA-transfected cells than that in the control siRNA-transfected cells, whereas untargeted protein expression levels were unchanged. In addition, since PRIP regulates soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) functions, we examined syntaxin1 and SNAP25 expression. The expression levels of syntaxin1 and SNAP25 in all knockdown cells examined were unchanged. We obtained similar results from 3 independent experiments, and a set of typical images is shown. (D) Insulin secretion assay using MIN6 cells. Cells were transfected with Gabarap-siRNA (2), Kif5b-siRNA (2), or Prip1-siRNA (3) and Prip2-siRNA (3), stimulated with 30 mM glucose, and then released insulin was measured every 1 min. Insulin secretion was normalized to intracellular insulin content, and is presented as a percentage of the total intracellular content. Values are presented as mean ± s.e. (n=3); *p<0.05; n.s., not statistically significant.
Fig. S2. Co-localization of phogrin and insulin-containing vesicles in MIN6 cells. Cells transfected with GFP-phogrin were fixed with 3.7% paraformaldehyde, subjected to immunocytochemistry with an anti-insulin antibody, and processed for confocal microscopy to detect phogrin (upper left panel) and insulin (upper right panel). The yellow and blue pseudo-colors in the PDM image show areas of high and low co-localization, respectively. Co-localization was analyzed by ImageJ intensity correlation analysis. Rr, Pearson’s correlation coefficient; R, Mander’s overlap coefficient; M1, Mander’s co-localization coefficient for insulin; M2, Mander’s co-localization coefficient for phogrin. We performed these experiments 3 times and obtained similar results. Scale bar: 5 μm.

Fig. S3. Silencing of Kif5b in MIN6 cells. (A) KIF5 subtype expression in MIN6 cells. The mRNA expression of Kif5a, Kif5b, and Kif5c in the mouse brain and MIN6 cells was analyzed by reverse transcription-polymerase chain reaction. (B) KIF5 expression in MIN6 cells. Cells transfected with or without Kif5b-siRNA (1) were fixed with 3.7% paraformaldehyde, subjected to immunocytochemistry with an anti-KIF5 antibody, and processed for confocal microscopy. The dotted line shows a cell edge. The graph shows the mean fluorescent intensity (arbitrary units) of KIF5 per cell. Values are presented as mean ± s.d. (n=40); ***p<0.001. (C) Co-localization of GABARAP (green) and insulin (red) in MIN6 cells transfected with either scrambled siRNA or Kif5b-siRNA (1). After a 10-min exposure to 30 mM glucose, cells were fixed with 3.7% paraformaldehyde for confocal microscopic observation. The yellow and blue pseudo-colors in the PDM images show areas of high and low co-localization, respectively. A set of typical images from 3 independent experiments is shown. The dotted line shows a cell edge. Each lower panel shows a magnified view of the framed area. The graph shows the overlap coefficient. Values are presented as mean ± s.d.; the difference is not statistically significant (from the left, n=114 and 195, respectively). Scale bars: 5 μm.
Fig. S4. Silencing of GABARAP in MIN6 cells. Cells transfected with or without Gabarap-siRNA were subjected to immunocytochemistry with an anti-GABARAP antibody. The dotted line shows a cell edge. The graph shows the mean fluorescent intensity (arbitrary units) of GABARAP per cell. Values are presented as mean ± s.d. (n=20); **p<0.01. Scale bar: 5 μm.

Fig. S5. Analyses of the involvement of GABARAP in insulin secretion. (A,B) MIN6 cells were transfected with scrambled siRNA (−) or Prp1-siRNA mix [Prp1-siRNAs (1, 2, 3) and Prp2-siRNAs (1, 2, 3)]. Two days after transfection, cultured cells were stimulated with or without 30 mM glucose for 10 min, and extracted with homogenization buffer. Equivalent protein amounts in the cell homogenates were fractionated in OptiPrep™ discontinuous gradients (3%, 7.5%, 18%, and 35%). The vesicle fraction (fraction 11 (Fig. 3)) was collected, and GABARAP content was analyzed by western blotting (A). The total amount of GABARAP in the whole cell homogenates from Prp1-knockdown and control cells did not differ (lowest blot in panel A). Three independent experiments were performed, and a set of typical images is shown. The mean values of the GABARAP bands are shown in the graph (B). Values are presented as mean ± s.d. (n=3); ***p<0.001. (C) A Halo-GABARAP40–67 peptide binds PRIP1. MIN6 cells transfected with a Halo-GABARAP40–67-plasmid or an empty vector were solubilized, and the resulting extract was immunoprecipitated with an anti-Halo antibody or control IgG. Then, western blotting was performed using an anti-PRIP1 antibody. Similar results were obtained in 3 additional experiments, and a set of typical images is shown. (D–F) Accumulation of GABARAP and KIF in insulin vesicle fractions from MIN6 cells transfected with GABARAP40–67. Cells were transfected with pIRES2-DsRed/GABARAP40–67, and then stimulated with 30 mM glucose for 10 min. Cell lysates were fractionated using OptiPrep™ discontinuous gradients (3%, 7.5%, 18%, and 35%). The secretory vesicle-rich fractions were analyzed by western blotting. Similar results were obtained from 3 independent experiments, and a set of typical images is shown (D). The total amounts of KIF5 and GABARAP in GABARAP40–67-transfected and control cells are similar (lowest blot in panel D). The density of each band was calculated, and the values of KIF5 (E) and GABARAP (F) are presented as arbitrary units based on phogrin density. Values are presented as mean ± s.d. (n=3); *p<0.05, **p<0.01. (G) Accumulation of GABARAP in insulin vesicle fractions from MIN6 cells after high glucose stimulation. The insulin vesicle fraction was prepared by fractionation using an OptiPrep™ discontinuous gradient, and western blotting was performed. Similar results were obtained from 3 independent experiments.
Fig. S6. Characterization of the fusion events during insulin secretion by two-photon imaging analysis using pancreatic islets. (A) PRIP expression in pancreatic islets. Pancreatic islets were enzymatically isolated from wild-type and Prip-DKO mouse pancreas. Homogenates of the isolated islets and a piece of cerebral cortex were analyzed by western blotting using anti-PRIP1 and anti-PRIP2 antibodies. (B–D) Characteristics of exocytic events in the islets isolated from wild-type and Prip-DKO mice were examined by two-photon microscopic observation. We analyzed 438 and 501 events in wild-type and Prip-DKO cells, respectively, in 5 independent experiments. The distribution of the maximum fluorescence intensity in each Ω-like profile (B). The time to reach the maximum intensity after glucose stimulation and the time to return to basal levels were calculated and shown in panels C and D, respectively.

Fig. S7. Comparison of the glucose-induced Ca\(^{2+}\) responses between wild-type and Prip-DKO cells. Two-photon calcium imaging was simultaneously performed with pancreatic islets isolated from wild-type and Prip-DKO mice, when the insulin exocytic events were visualized by high glucose stimulation (20 mM). Islets were loaded with the Ca\(^{2+}\) indicator fura-2-AM (10 μM) for 40 min at 37°C. Relative Ca\(^{2+}\) responses from more than 49 cells were analyzed in 3 independent experiments, and a set of typical Ca\(^{2+}\) responses is shown (A). Onset time (B), the relative maximum Ca\(^{2+}\) response (C), and the slope (from initiation until the point at which the maximal Ca\(^{2+}\) concentration was obtained) (D) were examined. Values are presented as mean ± s.d. (wild type, n=60; PRIP-DKO, n=49).
Fig. S8. KIF5, β-tubulin, and insulin localization in MIN6 cells transfected with Prp1-siRNA or Gabarap-siRNA.

Co-localization of KIF5 (green) and β-tubulin (red) (A), KIF5 (green) and insulin (red) (B), and β-tubulin (green) and insulin (red) (C) in MIN6 cells transfected with control siRNA (upper 2 panels) and Prp1-siRNA mix [Prp1-siRNAs (1, 2, 3) and Prp2-siRNAs (1, 2, 3)] (middle 2 panels) or Gabarap-siRNA (1) (lower 2 panels). After a 10-min exposure to 30 mM glucose, cells were fixed with 3.7% paraformaldehyde for confocal microscopic observation. The representative cells shown here are different from those shown in Fig. 2C–E and Fig. 4C–E. The framed area is magnified below in each set. Arrowheads indicate the co-localization of KIF5 and insulin (B). A set of typical images from more than 45 cells in 3 independent experiments is shown. Scale bars: 5 μm.
Fig. S9. Immunocytochemical analysis of MIN6 cells transfected with myc-GABARAP2–35 or Prip siRNA mix. Co-localization of KIF5 and insulin in MIN6 cells (A) transfected with a myc-empty vector (upper panels) or myc-GABARAP2–35 (lower panels), GABARAP (green) and insulin (red) (B), or β-tubulin (red) (C) in MIN6 cells transfected with scrambled siRNA (B,C, upper panels) or Prip-siRNA mix [Prip1-siRNAs (1, 2, 3) and Prip2-siRNAs (1, 2, 3) (B,C, lower panels)]. After a 10-min exposure to 30 mM glucose, cells were fixed with 3.7% paraformaldehyde for confocal microscopy. The representative cells shown here are different from those shown in Fig. 5A,B (B,C). The framed area is magnified below. A set of typical images from more than 81 cells in 3 independent experiments is shown. Arrowheads indicate the co-localization of GABARAP with insulin (B). Scale bars: 5 μm.
Fig. S10. Co-localization of GABARAP, insulin, β-tubulin, and KIF5 in MIN6 cells transfected with GABARAP40–67. Co-localization of GABARAP (green) and insulin (red) (A), GABARAP (green) and β-tubulin (red) (B), β-tubulin (green) and insulin (red) (C), KIF5 (green) and β-tubulin (red) (D), and KIF5 (green) and insulin (red) (E) in MIN6 cells transfected with a pIRES2-DsRed/empty vector (upper 2 panels) and pIRES2-DsRed/GABARAP40–67 (lower 2 panels). After a 10-min exposure to 30 mM glucose, cells were fixed with 3.7% paraformaldehyde, subjected to immunocytochemistry with each specific antibody, and analyzed by confocal microscopy. Endogenous GABARAP was stained using an anti-GABARAP antibody, which recognized amino acid residues 1–39 of GABARAP. The obtained blue images were replaced with red in the merged panels. The framed area is magnified (the lower panels in each). Arrowheads indicate the colocalization of GABARAP with insulin (A) and KIF5 with insulin (E). A set of typical images from more than 40 cells in 3 independent experiments is shown. Scale bars: 5 μm.